company background image
DHR

DanaherNYSE:DHR Stock Report

Last Price

US$280.45

Market Cap

US$200.4b

7D

-4.4%

1Y

17.8%

Updated

23 Jan, 2022

Data

Company Financials +
DHR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health3/6
Dividends0/6

DHR Stock Overview

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

Danaher Competitors

Thermo Fisher Scientific

NYSE:TMO

US$228.7b

Illumina

NasdaqGS:ILMN

US$57.2b

Agilent Technologies

NYSE:A

US$41.5b

Waters

NYSE:WAT

US$19.5b

Price History & Performance

Summary of all time highs, changes and price drops for Danaher
Historical stock prices
Current Share PriceUS$280.45
52 Week HighUS$333.96
52 Week LowUS$211.22
Beta0.70
1 Month Change-12.58%
3 Month Change-8.38%
1 Year Change17.82%
3 Year Change163.75%
5 Year Change246.41%
Change since IPO28,849.68%

Recent News & Updates

Dec 30
Danaher (NYSE:DHR) Has A Rock Solid Balance Sheet

Danaher (NYSE:DHR) Has A Rock Solid Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Dec 15
Here's Why I Think Danaher (NYSE:DHR) Is An Interesting Stock

Here's Why I Think Danaher (NYSE:DHR) Is An Interesting Stock

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

Dec 07

Danaher: A Jewel In The Crown

A number of subsidiaries are involved with the expanding market of biopharmaceuticals. Whilst it is true that revenue is growing for the Life Sciences division, it is not gaining market share. Danaher’s competitors are gaining.

Shareholder Returns

DHRUS Life SciencesUS Market
7D-4.4%-4.7%-6.1%
1Y17.8%1.8%4.2%

Return vs Industry: DHR exceeded the US Life Sciences industry which returned 1.8% over the past year.

Return vs Market: DHR exceeded the US Market which returned 4.2% over the past year.

Price Volatility

Is DHR's price volatile compared to industry and market?
DHR volatility
DHR Average Weekly Movement3.8%
Life Sciences Industry Average Movement9.1%
Market Average Movement6.7%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.4%

Stable Share Price: DHR is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: DHR's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196968,000Rainer Blairhttps://www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Danaher Fundamentals Summary

How do Danaher's earnings and revenue compare to its market cap?
DHR fundamental statistics
Market CapUS$200.40b
Earnings (TTM)US$5.64b
Revenue (TTM)US$28.07b

35.6x

P/E Ratio

7.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DHR income statement (TTM)
RevenueUS$28.07b
Cost of RevenueUS$11.02b
Gross ProfitUS$17.05b
ExpensesUS$11.41b
EarningsUS$5.64b

Last Reported Earnings

Oct 01, 2021

Next Earnings Date

Jan 27, 2022

Earnings per share (EPS)7.89
Gross Margin60.75%
Net Profit Margin20.08%
Debt/Equity Ratio54.3%

How did DHR perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

10%

Payout Ratio

Valuation

Is Danaher undervalued compared to its fair value and its price relative to the market?

2.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DHR ($280.45) is trading below our estimate of fair value ($287.63)

Significantly Below Fair Value: DHR is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: DHR is good value based on its PE Ratio (35.6x) compared to the US Life Sciences industry average (39.3x).

PE vs Market: DHR is poor value based on its PE Ratio (35.6x) compared to the US market (16.5x).


Price to Earnings Growth Ratio

PEG Ratio: DHR is poor value based on its PEG Ratio (5.7x)


Price to Book Ratio

PB vs Industry: DHR is overvalued based on its PB Ratio (5x) compared to the US Life Sciences industry average (3.2x).


Future Growth

How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

6.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DHR's forecast earnings growth (6.3% per year) is above the savings rate (2%).

Earnings vs Market: DHR's earnings (6.3% per year) are forecast to grow slower than the US market (13% per year).

High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.

Revenue vs Market: DHR's revenue (6% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: DHR's revenue (6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (13%).


Past Performance

How has Danaher performed over the past 5 years?

18.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DHR has high quality earnings.

Growing Profit Margin: DHR's current net profit margins (20.1%) are higher than last year (15.1%).


Past Earnings Growth Analysis

Earnings Trend: DHR's earnings have grown by 18.5% per year over the past 5 years.

Accelerating Growth: DHR's earnings growth over the past year (82.9%) exceeds its 5-year average (18.5% per year).

Earnings vs Industry: DHR earnings growth over the past year (82.9%) exceeded the Life Sciences industry 72.2%.


Return on Equity

High ROE: DHR's Return on Equity (13.3%) is considered low.


Financial Health

How is Danaher's financial position?


Financial Position Analysis

Short Term Liabilities: DHR's short term assets ($10.8B) exceed its short term liabilities ($7.3B).

Long Term Liabilities: DHR's short term assets ($10.8B) do not cover its long term liabilities ($31.8B).


Debt to Equity History and Analysis

Debt Level: DHR's net debt to equity ratio (48.4%) is considered high.

Reducing Debt: DHR's debt to equity ratio has increased from 36.1% to 54.3% over the past 5 years.

Debt Coverage: DHR's debt is well covered by operating cash flow (34.9%).

Interest Coverage: DHR's interest payments on its debt are well covered by EBIT (31.5x coverage).


Balance Sheet


Dividend

What is Danaher current dividend yield, its reliability and sustainability?

0.30%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: DHR's dividend (0.3%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.37%).

High Dividend: DHR's dividend (0.3%) is low compared to the top 25% of dividend payers in the US market (3.6%).


Stability and Growth of Payments

Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DHR is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Rainer Blair (57 yo)

1.33yrs

Tenure

US$10,396,761

Compensation

Mr. Rainer M. Blair serves as President, Chief Executive Officer and Director at Danaher Corporation since September 1, 2020. Mr. Blair served as an Executive Vice President of Danaher Corporation since Ja...


CEO Compensation Analysis

Compensation vs Market: Rainer's total compensation ($USD10.40M) is about average for companies of similar size in the US market ($USD11.47M).

Compensation vs Earnings: Rainer's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: DHR's management team is considered experienced (4.1 years average tenure).


Board Members

Experienced Board: DHR's board of directors are seasoned and experienced ( 14.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DHR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Danaher Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Danaher Corporation
  • Ticker: DHR
  • Exchange: NYSE
  • Founded: 1969
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$200.403b
  • Shares outstanding: 714.58m
  • Website: https://www.danaher.com

Number of Employees


Location

  • Danaher Corporation
  • 2200 Pennsylvania Avenue, NW
  • Suite 800W
  • Washington
  • District Of Columbia
  • 20037-1701
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 23:07
End of Day Share Price2022/01/21 00:00
Earnings2021/10/01
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.